Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing
Having already nailed down multiple licensing and collaboration deals with Big Pharma giants like Bristol Myers Squibb and Pfizer, a France- and Quebec-based GPCR biotech now has its first VC financing round under its belt.
The I/O focused biotech Domain Therapeutics closed a Series A worth $42 million, the company announced Tuesday — which will last two years, according to CEO Pascal Neuville. Domain had previously built numerous partnerships with different pharma companies since its founding in 2008, such as Merck KGaA, Takeda and Boehringer Ingelheim.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.